JP2024511767A5 - - Google Patents
Info
- Publication number
- JP2024511767A5 JP2024511767A5 JP2023557719A JP2023557719A JP2024511767A5 JP 2024511767 A5 JP2024511767 A5 JP 2024511767A5 JP 2023557719 A JP2023557719 A JP 2023557719A JP 2023557719 A JP2023557719 A JP 2023557719A JP 2024511767 A5 JP2024511767 A5 JP 2024511767A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- human subject
- administered
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163168972P | 2021-03-31 | 2021-03-31 | |
| US63/168,972 | 2021-03-31 | ||
| PCT/US2022/022485 WO2022212459A1 (en) | 2021-03-31 | 2022-03-30 | Treatment of amyotrophic lateral sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024511767A JP2024511767A (ja) | 2024-03-15 |
| JP2024511767A5 true JP2024511767A5 (https=) | 2025-04-08 |
Family
ID=81346346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557719A Pending JP2024511767A (ja) | 2021-03-31 | 2022-03-30 | 筋萎縮性側索硬化症の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240182903A1 (https=) |
| EP (1) | EP4314294A1 (https=) |
| JP (1) | JP2024511767A (https=) |
| KR (1) | KR20230172502A (https=) |
| CN (1) | CN117062911A (https=) |
| AU (1) | AU2022252236A1 (https=) |
| BR (1) | BR112023019877A2 (https=) |
| CA (1) | CA3214585A1 (https=) |
| MX (1) | MX2023011214A (https=) |
| TW (1) | TW202304471A (https=) |
| WO (1) | WO2022212459A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120350010B (zh) * | 2025-06-24 | 2025-09-09 | 羿美诚健(上海)生物医药有限公司 | 靶向PIKfyve基因的小核酸及其药物组合物和用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2452458A1 (en) | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| HUE050704T2 (hu) | 2014-04-01 | 2020-12-28 | Biogen Ma Inc | Összetételek a SOD-1 expressziójának modulálására |
| TWI906204B (zh) * | 2018-12-14 | 2025-12-01 | 美商百健Ｍａ公司 | 用於治療及預防肌肉萎縮性脊髓側索硬化症之組合物及方法 |
-
2022
- 2022-03-30 BR BR112023019877A patent/BR112023019877A2/pt unknown
- 2022-03-30 JP JP2023557719A patent/JP2024511767A/ja active Pending
- 2022-03-30 CN CN202280024040.2A patent/CN117062911A/zh active Pending
- 2022-03-30 EP EP22717995.9A patent/EP4314294A1/en active Pending
- 2022-03-30 US US18/283,526 patent/US20240182903A1/en active Pending
- 2022-03-30 TW TW111112225A patent/TW202304471A/zh unknown
- 2022-03-30 AU AU2022252236A patent/AU2022252236A1/en active Pending
- 2022-03-30 CA CA3214585A patent/CA3214585A1/en active Pending
- 2022-03-30 WO PCT/US2022/022485 patent/WO2022212459A1/en not_active Ceased
- 2022-03-30 KR KR1020237037099A patent/KR20230172502A/ko active Pending
- 2022-03-30 MX MX2023011214A patent/MX2023011214A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xia et al. | GLS1-mediated glutaminolysis unbridled by MALT1 protease promotes psoriasis pathogenesis | |
| JP6608309B2 (ja) | Ｃｍｔ及び関連疾患の処置のための新規な治療的アプローチ | |
| JP2022513721A5 (https=) | ||
| US11680266B2 (en) | Endomucin inhibitor as an anti-angiogenic agent | |
| JP7345466B2 (ja) | アンチセンスオリゴヌクレオチドを含有する組成物およびデュシェンヌ型筋ジストロフィーの治療へのその使用 | |
| Tomar et al. | Insight into the pivotal role of signaling pathways in psoriasis pathogenesis, potential therapeutic molecules and drug delivery approaches | |
| JP7543278B2 (ja) | 有機化合物 | |
| KR102821047B1 (ko) | 근위축 측삭 경화증의 치료 및 방지를 위한 조성물 및 방법 | |
| KR20210008498A (ko) | Fxi 발현을 감소시키기 위한 화합물 및 방법 | |
| TW201919655A (zh) | 治療肌肉萎縮症的方法 | |
| Boujon et al. | Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice | |
| CN104955451A (zh) | 恩他卡朋在预防或治疗肥胖等代谢综合征中的应用 | |
| US11660306B2 (en) | Treatment of Rett syndrome | |
| Cheng et al. | Identification of a novel hybridization from isosorbide 5-mononitrate and bardoxolone methyl with dual activities of pulmonary vasodilation and vascular remodeling inhibition on pulmonary arterial hypertension rats | |
| Sunilkumar et al. | REDD1-dependent GSK3β dephosphorylation promotes NF-κB activation and macrophage infiltration in the retina of diabetic mice | |
| WO2022271808A1 (en) | Novel rna therapeutics and uses thereof | |
| KR20220035137A (ko) | Ppm1a 억제제 및 그의 사용 방법 | |
| JP2024511767A5 (https=) | ||
| US20200080155A1 (en) | Dot1l inhibitors and uses thereof | |
| Sayed et al. | JAK1 rs310241 and JAK3 rs3008 genotypes may increase susceptibility to psoriasis: a case control study | |
| US6214571B1 (en) | Method for inhibiting adenylosuccinate synthetase activity in malignant methylthioadenosine phosphorylase deficient cells | |
| JP2024511767A (ja) | 筋萎縮性側索硬化症の治療 | |
| KR20220152569A (ko) | 프리칼리크레인-연합된 병태를 치료하고 예방하는 조성물 및 방법 | |
| RU2824046C2 (ru) | Составы для лечения и предотвращения бокового амиотрофического склероза | |
| Li et al. | Effects of anti-tuberculosis drugs on the proliferation and differentiation of alveolar stem cells |